AboutChad O’Connor

As a key member of Sg2’s product strategy and management team, Chad oversees the positioning and development of the Sg2 Analytics platform. With a deep understanding of the current issues facing health system executives, he crafts the platform to address their needs.

Chad also works directly with many Sg2 clientele to help them understand analytics data reports, uncover meaningful data trends within those reports and access additional Sg2 resources to drive improvement. He is a frequent speaker at various venues, from national conferences to board meetings, on topics ranging from overall health care trends to service line growth strategies and is on the faculty for Sg2 educational offerings.

Previously, Chad led Sg2’s service delivery, managing all client-facing personnel. He was also the cardiovascular solutions lead, producing content on myriad topics, including congestive heart failure disease management, transcatheter aortic valve replacement, strategic cardiovascular service line growth, and clinical, operational and financial performance improvement. In addition, Chad attracted new organizations to join Sg2’s community of leading-practice cardiovascular programs.

Chad earned MS and BS degrees in biology from the University of Illinois at Urbana-Champaign. He has held positions as a research pharmacologist at Abbott Laboratories and as a senior professional representative for Merck & Co, earning several awards at each organization.

"Analytics and expertise to help you understand market dynamics and capitalize opportunities for growth."

As of February 11, 2016, Vizient, Inc. has completed its purchase of MedAssets Sg2 and spend and clinical resource management segments from Pamplona Capital Management, LLC. MedAssets revenue cycle business will continue to operate as a wholly-owned subsidiary of Pamplona Capital Management LLP.

Follow Sg2 on Twitter Connect with Sg2 on LinkedIn Watch Sg2 on YouTube